|
Register by
July 20th and SAVE up to $350!
|
|
SCREENING AGAINST MULTIPLE TARGETS
(Shared session with Drug Repositioning Summit)
|
Featured Presentation
Is Repositioning a Viable Option for Creating Differentiated Medicines?
Lee E. Babiss, Ph.D., Vice President, Preclinical R&D, F. Hoffmann-La Roche
Inc.
Automated Robotic Molecular Profiling in Cells for New Therapeutic Directions
Jeremy S. Caldwell, Ph.D., Director of Molecular and Cell Biology, Genomics
Institute of the Novartis Research Foundation
An Efficient Platform for Genetic Target and Compound Positioning
David Grass, Ph.D, Vice President, Scientific Operations, Caliper Discovery
Alliances and Services, Caliper Life Sciences
Broad-Scale in Vitro Pharmacology Profiling to Predict Clinical Adverse
Effects and for ADME Profiling
Laszlo Urban, Ph.D., Executive Director, Preclinical Profiling Group, Novartis
Institute for Biomedical Research (invited)
Ceftriaxone and Results of Large Scale Screening Efforts
Jill Heemskerk, Ph.D., Extramural Research Program Neuroscience, National
Institute of Neurological Disorders and Stroke
Panel Discussion: How to Choose a Compound with the Best Profile
|
LINKING CHEMICAL STRUCTURE TO
BIOLOGICAL ACTIVITY FOR PRIORITIZING HITS
|
Rethinking Similarity & the Chemotype Concept: Using Biological
Fingerprints as a More Relevant Descriptor
Jonathan Mason, Ph.D., Divisional Director, Early Lead Generation and
Computational Chemistry, Lundbeck Research DK (Denmark)
Linking Chemical Structure Data to Biological Activity and Clinical
Information
Tudor I. Oprea, Ph.D., Professor & Chief, Biochemistry & Molecular
Biology Biocomputing, University of New Mexico
Mark Murcko, Ph.D., Vice President and Chief Technical Officer, Vertex
Pharmaceuticals, Inc.
Prioritizing Hits from Phenotypic Assays Using Biochemical Profiling Data
Jeffrey J. Sutherland, Ph.D., Computational Scientist, Discovery Informatics,
Lilly Indianapolis
Molecular Profiling Driven Drug Discovery: Use of Compound Profiling from
Discovery to the Clinic and Back Again
Stephen Horrigan, Ph.D., Vice President of Research, Avalon Pharmaceuticals
Panel Discussion: The Value of Doing Systems Biology after HTS
Moderator: Mark Murcko, Ph.D.
Additional Panelist:
Berta Strulovici, Ph.D., Research Vice President, Automated Biotechnology, Merck
Research Laboratories
- How to use model systems coupled with multiparametric assays
- Do systems biology assay data extrapolate well to humans?
- What is the best order to do assays, parallel vs. sequential?
- How predictive are the results?
- What have people learned?
|
PROFILING TO PREDICT ADVERSE
EVENTS AND
OFF-TARGET ACTIVITY
|
Differentiating Leads from Candidates
Dana A. Vanderwall, Ph.D., Structural Chemistry, GlaxoSmithKline
Analysis of Drug Induced Effect Patterns for Investigating Systems Structure
Effect Relationships
William T. Loging, Ph.D., Principal Scientist, Medicinal Sciences, Pfizer Global
R&D Groton Labs
Characterizing the Multiple Activities of Kinase Inhibitors
Petra Ross-Macdonald, Ph.D., Senior Research Investigator, Applied Genomics,
Bristol-Myers Squibb Co.
Chemogenomics Strategies for GPCR Hit Finding
Wolfgang Guba, F. Hoffmann-La Roche, Inc.
Compound Profiling by Predicting On-Target Activities, Compound Promiscuity
and Adverse Drug Reactions
Andreas Bender, Ph.D., Lead Discovery Informatics, Center for Proteomic
Chemistry, Novartis Institutes for BioMedical Research, Inc.
Interpreting Compound Profiles in the Context of the Human Drug Experience
Jacques Migeon, Ph.D., Senior Scientist, BioPrint, CEREP Inc.
Panel Discussion: Comparing and Contrasting Available Databases, Public vs.
Private
|
|
